RxDoctor Payments Data

Thomas Sisk, MD

Family Medicine · Finleyville, PANPI 1710985932

Payments from drug & device makers

$7,148in general payments, 2019–2025

Across 402 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AstraZeneca$899
  • Pfizer$838
  • Philips North America LLC$446
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$7,141100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,148 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,328
Medicare patients
71
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$122,024
EliquisApixaban111$98,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$90,189
MounjaroTirzepatide47$52,047
RybelsusSemaglutide41$50,688
JardianceEmpagliflozin47$50,190
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr65$35,070
FarxigaDapagliflozin Propanediol33$30,478
TrulicityDulaglutide15$15,863
Humalog Kwikpen U-200Insulin Lispro13$11,418
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,178
XareltoRivaroxaban14$10,595
Breo ElliptaFluticasone/Vilanterol17$7,394
JanuviaSitagliptin Phosphate12$6,890
Atorvastatin Calcium561$4,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,215$172,713165 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,462$132,653199 claims
PfizerEliquis$838$98,179111 claims
Lilly USA, LLCMounjaro, Trulicity$1,224$67,91062 claims
Boehringer IngelheimJardiance$60$50,19047 claims
AstraZenecaFarxiga, Breztri Aerosphere$899$41,65549 claims
AbbVieSynthroid$295$89720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Finleyville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →